Pherecydes Pharma Obtains €2 Million in Non-dilutive Financing From Bpifrance
29 Aprile 2021 - 6:00PM
Business Wire
This financing has been granted within the
framework of the “State-Guaranteed Loan - Innovation Support”
scheme
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 – ALPHE), a
biotechnology company specializing in precision phage therapy to
treat resistant and/or complicated bacterial infections, today
announces that it has obtained, within the framework of a
“State-Guaranteed Loan – Innovation Support”, a €2 million loan
from Bpifrance, the French public investment bank.
This interest-bearing loan benefits from a one-year deferred
repayment and Pherecydes Pharma will have the possibility, after
the first year, of amortizing the loan over a duration of up to 5
years.
Guy-Charles Fanneau de La Horie, Chairman of the Executive
Board of Pherecydes Pharma, states: “We are very pleased to
strengthen our cash position through the granting of this
non-dilutive financing of €2 million. We would like to thank
Bpifrance for the support it has thus demonstrated for our
projects, 2021 being a pivotal year for our development with the
launch of clinical trials for our anti-Staphylococcus aureus phages
and the implementation of Early Access Programs (EAP) expected
during the 2nd half of the year”.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company
that develops treatments against resistant bacterial infections,
responsible for many serious infections. The Company has developed
an innovative approach, precision phage therapy, based on the use
of phages, natural bacteria-killing viruses. Pherecydes Pharma is
developing a portfolio of phages targeting 3 of the most resistant
and dangerous bacteria, which alone account for more than two
thirds of hospital-acquired resistant infections: Staphylococcus
aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of
precision phage therapy has been successfully applied in 26
patients in the context of compassionate use, under the supervision
of the French National Agency for the Safety of Medicines (ANSM).
Headquartered in Nantes, Pherecydes Pharma has a team of around
twenty experts from the pharmaceutical industry, biotechnology
sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but
not limited to, certain statements regarding future results and
other future events. These statements are based on the current
vision and assumptions of the management of the Company. They
incorporate known and unknown risks and uncertainties that could
result in significant differences in results, profitability and
expected events. In addition, Pherecydes Pharma, its shareholders
and its affiliates, directors, officers, counsels and employees
have not verified the accuracy of, and make no representations or
warranties about, statistical information or forecast information
contained within this news release and that originates or is
derived from third party sources or industry publications; these
statistical data and forecast information are only used in this
press release for information purposes. Finally, this press release
may be drafted in French and in English. In the event of
differences between the two texts, the French version will
prevail.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005793/en/
Pherecydes Pharma Philippe Rousseau CFO
investors@pherecydes-pharma.com
NewCap Dusan Oresansky Investor Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 98